QuantalX Neuroscience Introduces Groundbreaking Delphi-MD Device for Brain Health Assessment in Europe

QuantalX Neuroscience has achieved a significant milestone with the CE MDR approval for its Delphi-MD device, a groundbreaking solution for brain health assessment.

This certification, granted under the European Union’s Medical Device Regulation (MDR), establishes high standards for safety, efficacy, and quality in medical devices.

The approval reinforces QuantalX’s commitment to advancing neurological care through innovation.

With this certification, QuantalX is set to expand the commercial reach of its objective neurodiagnostic technology across Europe.

The Delphi-MD device will be introduced in neurological care centres, neurology departments, and brain health networks. It is designed to improve brain health assessments, facilitate early detection, and support differential diagnosis of neurological conditions such as stroke, Parkinson’s disease, dementia, Alzheimer’s disease, and Normal Pressure Hydrocephalus (NPH).

The device also assists in predicting individual responses to treatment, enhancing patient care and clinical decision-making.

The Delphi-MD device offers an innovative approach to early detection and precise diagnosis of neurological disorders, helping to improve patient outcomes and quality of life.

Its implementation aims to reduce the clinical and economic burden on healthcare systems by enabling more effective management of brain health conditions.